7.94
price up icon15.16%   1.045
after-market 시간 외 거래: 7.96 0.02 +0.25%
loading
전일 마감가:
$6.895
열려 있는:
$7
하루 거래량:
211.76K
Relative Volume:
3.80
시가총액:
$29.22M
수익:
-
순이익/손실:
$-31.11M
주가수익비율:
-5.1895
EPS:
-1.53
순현금흐름:
$-28.18M
1주 성능:
+29.53%
1개월 성능:
+15.91%
6개월 성능:
-30.36%
1년 성능:
-82.09%
1일 변동 폭
Value
$7.00
$8.8861
1주일 범위
Value
$5.92
$8.8861
52주 변동 폭
Value
$5.3495
$44.33

Tempest Therapeutics Inc Stock (TPST) Company Profile

Name
명칭
Tempest Therapeutics Inc
Name
전화
415-798-8589
Name
주소
2000 SIERRA POINT PARKWAY, BRISBANE
Name
직원
5
Name
트위터
Name
다음 수익 날짜
2025-03-26
Name
최신 SEC 제출 서류
Name
TPST's Discussions on Twitter

TPST을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
TPST
Tempest Therapeutics Inc
7.94 22.57M 0 -31.11M -28.18M -1.53
Biotechnology icon
ONC
Beone Medicines Ltd Adr
257.00 26.69B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.82 114.81B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.282 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
85.54 6.60B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
483.07 65.36B 14.09B 4.50B 2.96B 39.28

Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-10 다운그레이드 H.C. Wainwright Buy → Neutral
2025-04-10 다운그레이드 Scotiabank Sector Outperform → Sector Perform
2024-03-14 개시 Scotiabank Sector Outperform
2024-02-08 개시 Jefferies Buy

Tempest Therapeutics Inc 주식(TPST)의 최신 뉴스

pulisher
10:35 AM

Tempest Therapeutics stock rises on EMA Orphan Drug Designation - Investing.com

10:35 AM
pulisher
08:53 AM

Tempest Therapeutics Says Amezalpat Gets EMA Orphan Drug Designation in Liver Cancer - marketscreener.com

08:53 AM
pulisher
08:46 AM

Tempest Therapeutics: European Medicines Agency Grants Orphan Drug Designation To Amezalpat - Nasdaq

08:46 AM
pulisher
08:16 AM

TPST Receives EMA Orphan Drug Designation for Liver Cancer Treatment | TPST Stock News - GuruFocus

08:16 AM
pulisher
08:04 AM

Tempest Receives Orphan Drug Designation from the European - GlobeNewswire

08:04 AM
pulisher
May 23, 2025

Tempest Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 23, 2025
pulisher
May 19, 2025

HC Wainwright Issues Optimistic Estimate for TPST Earnings - Defense World

May 19, 2025
pulisher
May 16, 2025

Tempest Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025
pulisher
May 16, 2025

Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace

May 16, 2025
pulisher
May 14, 2025

TPST Highlights Promising Data for Cancer Therapy | TPST Stock N - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Tempest Therapeutics Q1 Operating Income USD -10.936 Million - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Tempest Therapeutics Reports Positive Amezalpat Data and FDA Designations for Cancer Treatment Programs - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

FDA Grants Multiple Key Designations to Tempest Cancer Drugs as New AACR Data Shows Promise - Stock Titan

May 13, 2025
pulisher
May 11, 2025

Millendo Therapeutics, Inc. Announces Board Changes - marketscreener.com

May 11, 2025
pulisher
May 08, 2025

Cash-strapped Bay Area biotech company lays off all but 5 employees - MSN

May 08, 2025
pulisher
May 05, 2025

Tempest Therapeutics Inc expected to post a loss of $3.29 a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 04, 2025

Geode Capital Management LLC Has $296,000 Stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

May 04, 2025
pulisher
Apr 30, 2025

XTX Topco Ltd Has $134,000 Position in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

Apr 30, 2025
pulisher
Apr 29, 2025

Tempest Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Canada

Apr 29, 2025
pulisher
Apr 28, 2025

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - The Manila Times

Apr 28, 2025
pulisher
Apr 28, 2025

Tempest Therapeutics Presents Promising Amezalpat Data at 2025 AACR Annual Meeting, Supporting Novel Cancer Treatment Mechanism - Nasdaq

Apr 28, 2025
pulisher
Apr 28, 2025

Tempest Presents New Amezalpat MOA Data Reinforcing Its - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

Breakthrough: New Cancer Drug Amezalpat Demonstrates Dual Anti-Cancer Mechanism in Multiple Tumors - Stock Titan

Apr 28, 2025
pulisher
Apr 28, 2025

Tempest Therapeutics regains Nasdaq compliance - Investing.com

Apr 28, 2025
pulisher
Apr 27, 2025

Market Recap Check: Tempest Therapeutics Inc (TPST)’s Negative Finish at 0.61, Up/Down -14.53 - DWinneX

Apr 27, 2025
pulisher
Apr 24, 2025

Struggling Bay Area biotech company, once worth $1B, lays off all but 5 workers - SFGATE

Apr 24, 2025
pulisher
Apr 22, 2025

Tempest Therapeutics - The Pharma Letter

Apr 22, 2025
pulisher
Apr 21, 2025

Tempest Therapeutics stock rises on FDA Orphan Drug Designation By Investing.com - Investing.com Nigeria

Apr 21, 2025
pulisher
Apr 21, 2025

Tempest Therapeutics stock rises on FDA Orphan Drug Designation - Investing.com Australia

Apr 21, 2025
pulisher
Apr 21, 2025

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - The Manila Times

Apr 21, 2025
pulisher
Apr 21, 2025

FDA Awards Rare Disease Drug Status to Tempest's Novel FAP Treatment: Phase 2 Trial Coming in 2025 - Stock Titan

Apr 21, 2025
pulisher
Apr 19, 2025

Tempest to explore alternatives to advance promising pipeline - The Pharma Letter

Apr 19, 2025
pulisher
Apr 13, 2025

TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up - MSN

Apr 13, 2025
pulisher
Apr 12, 2025

Scotiabank Reaffirms “Sector Perform” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

HC Wainwright Reaffirms Neutral Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger - Asianet Newsable

Apr 11, 2025
pulisher
Apr 10, 2025

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

Tempest seeks strategic alternatives as cash runs out for Phase 3 trial - BioPharma Dive

Apr 10, 2025
pulisher
Apr 10, 2025

HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

Tempest hits funding block for Phase III liver cancer drug-in-waiting - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Tempest seeks strategic alternatives to fund Phase 3 liver cancer trial - Endpoints News

Apr 10, 2025
pulisher
Apr 09, 2025

Tempest Therapeutics evaluates strategic options amid advancements By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Tempest Therapeutics Terminates Loan Agreement with Oxford - TipRanks

Apr 09, 2025
pulisher
Apr 09, 2025

Tempest Therapeutics Seeks Partner as It Explores Strategic Alternatives - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Tempest Therapeutics Mulls Alternatives to Advance Cancer Treatment Programs - marketscreener.com

Apr 09, 2025

Tempest Therapeutics Inc (TPST) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$1.15
price down icon 0.86%
$580.59
price up icon 1.24%
$308.00
price up icon 0.88%
$36.54
price up icon 1.27%
$4.8111
price up icon 1.29%
$483.07
price down icon 0.38%
자본화:     |  볼륨(24시간):